Hiroaki Okamoto

Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301)

Shinji Atagi, Masaaki Kawahara, Akira Yokoyama et al. · The Lancet Oncology · 2012 · 232 citations

Adaptive Radiotherapy, Radiation Medicine, Radiation Therapy +8

Phase II Trial of Amrubicin for Treatment of Refractory or Relapsed Small-Cell Lung Cancer: Thoracic Oncology Research Group Study 0301

Sayaka Onoda, Noriyuki Masuda, Takashi Seto et al. · Journal of Clinical Oncology · 2006 · 226 citations

Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer

Seiji Niho, Hideo Kunitoh, Hiroshi Nokihara et al. · Lung Cancer · 2012 · 211 citations · Full text

Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702

Hiroaki Okamoto, Kenji Watanabe, Hiroshi Kunikane et al. · British Journal of Cancer · 2007 · 210 citations · Full text

Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial

Kōichi Goto, Yuichiro Ohe, Taro Shibata et al. · The Lancet Oncology · 2016 · 147 citations

Second-line Treatment, Medicine, Randomised Phase 3 +9